Brachytherapy approach using 177Lu conjugated gold nanostars and evaluation of biodistribution, tumor retention, dosimetry and therapeutic efficacy in head and neck tumor model

Min Ying Lin, Hsin Hua Hsieh, Jyh-Cheng Chen, Chuan-Lin Chen, Nin Chu Sheu, Wen Sheng Huang, Shinn-Ying Ho, Ting-Wen Chen, Yi-Jang Lee*, Chun-Yi Wu

*此作品的通信作者

研究成果: Article同行評審

摘要

Brachytherapy can provide sufficient doses to head and neck squamous cell carcinoma (HNSCC) with minimal damage to nearby normal tissues. In this study, the β-emitter177 Lu was conjugated to DTPA-polyethylene glycol (PEG) decorated gold nanostars (177 Lu-DTPA-pAuNS) used in surface-enhanced Raman scattering and photothermal therapy (PTT). The accumulation and therapeutic efficacy of177 Lu-DTPA-pAuNS were compared with those of177 Lu-DTPA on an orthotopic HNSCC tumor model. The SPECT/CT imaging and biodistribution studies showed that177 Lu-DTPA-pAuNS can be accumulated in the tumor up to 15 days, but177 Lu-DTPA could not be detected at 24 h after injection. The tumor viability and growth were suppressed by injected177 Lu-DTPA-pAuNS but not nonconjugated177 Lu-DTPA, as evaluated by bioluminescent imaging. The radiation-absorbed dose of the normal organ was the highest in the liver (0.33 mSv/MBq) estimated in a 73 kg adult, but that of tumorsphere (0.5 g) was 3.55 mGy/MBq, while intravenous injection of177 Lu-DTPA-pAuNS resulted in 1.97 mSv/MBq and 0.13 mGy/MBq for liver and tumorsphere, respectively. We also observed further enhancement of tumor-suppressive effects by a combination of177 Lu-DTPA-pAuNS and PTT compared to177 Lu-DTPA-pAuNS alone. In conclusion,177 Lu-DTPA-pAuNS may be considered as a potential radiopharmaceutical agent for HNSCC brachytherapy.

原文English
文章編號1903
頁(從 - 到)1-13
頁數13
期刊Pharmaceutics
13
發行號11
DOIs
出版狀態Published - 11月 2021

指紋

深入研究「Brachytherapy approach using 177Lu conjugated gold nanostars and evaluation of biodistribution, tumor retention, dosimetry and therapeutic efficacy in head and neck tumor model」主題。共同形成了獨特的指紋。

引用此